Publication | Closed Access

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

HepatologyHepatitis CViral HepatitisAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirologyAntiviral DrugMedicineSofosbuvir Fixed-dose CombinationGenotype 1